Ruettgers Joins Lumicell Board

Facebook X LinkedIn Email
WELLESLEY, Mass., Sept. 14, 2018 — Michael Ruettgers has been appointed to the board of directors for molecular imaging technology developer Lumicell Inc.

“We are excited to add Mike’s leadership to our board,” said Andrey Zarur, chairman of Lumicell’s board of directors. “He knows how to build winning teams and has experience in bringing quality products and services to life. His decades of experience in scaling global businesses – and in healthcare, technology, and regulatory issues – will help us think bigger and drive long-term growth.”

Ruettgers is a retired special advisor to EMC Corp., where he previously held leadership roles, including executive chairman of the board, CEO, and president. Under Ruettgers’ leadership, EMC became the global leader in the storage network market and one of the fastest-growing companies in the U.S., and it achieved the highest single-decade performance of any listed stock in the history of the New York Stock Exchange.

“I’m thrilled to play a role in Lumicell’s growth,” Ruettgers said. “It’s important to get the company’s groundbreaking technology into the hands of physicians where it can improve patient outcomes and reduce health care costs. It’s exhilarating to work with growing companies like Lumicell, as they have the potential for the largest amount of growth and industry impact. The company’s core technologies will benefit patients and physicians [and] health care practices, [and they will] support the company, and encourage stakeholders.”

A frequent author on key policy and technology issues, Ruettgers was named one of the World's Top 25 Executives by Businessweek; one of the Best CEOs in America by Worth magazine; one of the 25 Most Powerful People in Networking in 2000 by NetworkWorld; and CEO of the Year for 2000 by Massachusetts Investor's Digest. He holds a bachelor’s degree from Idaho State University and an MBA from Harvard Business School.

Lumicell develops novel systems that enable real-time detection of tumor tissue in patients.

Published: September 2018
BusinessMichael RuettgersLumicellboard of directorsImagingpeople

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.